Patents Assigned to Genentech
  • Publication number: 20240390488
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: January 31, 2024
    Publication date: November 28, 2024
    Applicant: Genentech, Inc.
    Inventor: Melissa JUNTTILA
  • Publication number: 20240390287
    Abstract: Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. In some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly, and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.
    Type: Application
    Filed: April 22, 2024
    Publication date: November 28, 2024
    Applicant: GENENTECH, INC.
    Inventors: Yuchen FAN, Chun-Wan YEN, Ke ZHANG
  • Patent number: 12152054
    Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: November 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Hui F. Liu, Brian David Kelley, Deanna E. Myers, Beth McCooey, Krista Marie Petty
  • Patent number: 12152040
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: November 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Robert Anthony Blake, Peter Dragovich, Lewis J. Gazzard, Susan Kaufman, Tracy Kleinheinz, Thomas Pillow, Steven T. Staben, Binqing Wei
  • Publication number: 20240384000
    Abstract: The invention provides anti-Jagged1 antibodies and methods of using the same.
    Type: Application
    Filed: January 18, 2024
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
  • Publication number: 20240383915
    Abstract: Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: April 6, 2022
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Elizabeth H. KELLEY, Matthew Leo LANDRY, Sushant MALHOTRA, Benjamin David RAVETZ, Michael SIU, Jack Alexander TERRETT, BinQing WEI, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE, Guosheng WU, Yinlei SUN, Cheng SHAO, Aijun LU, Yulai ZHANG
  • Publication number: 20240383897
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Application
    Filed: March 13, 2024
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
  • Patent number: 12145998
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: November 19, 2024
    Assignee: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 12145997
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: April 26, 2024
    Date of Patent: November 19, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Patent number: 12139482
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventor: Snahel Patel
  • Patent number: 12139496
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
  • Patent number: 12141968
    Abstract: In one embodiment, a method includes, for each of a set of samples, receiving data input that includes dimensions of a sample area, a percentage of the sample area being viable cells, and a percentage of the sample area exhibiting necrosis. The method includes, for each of the set of samples, computing a percentage of the sample area being stroma. The method includes, for each of the set of samples, computing weighting factors. The method includes computing a weighted percentage of the set of samples being viable cells based on the computed weighting factor and percentage of the sample area being viable cells for each of the set of samples. The method includes determining that a specified condition is detected in the set of samples based on the computed weighted percentage of the set of samples being viable cells satisfying a threshold correlating with an indication of the specified condition.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: November 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Anjali Saqi, Shawn Wen Sun, Kosei Tajima, Barbara Jennifer Gitlitz
  • Publication number: 20240369575
    Abstract: Multispecific antibodies comprising a first half antibody comprising a first antigen binding site that binds to a polyubiquitin; and a second half antibody comprising a second antigen binding site that binds a pro-inflammatory protein, such as receptor-interacting protein kinase 1 (RIP1) or receptor-interacting protein kinase 2 (RIP2), as well as methods for using the antibodies, are provided.
    Type: Application
    Filed: February 26, 2024
    Publication date: November 7, 2024
    Applicant: Genentech, Inc.
    Inventors: Marissa Lynn MATSUMOTO, Domagoj VUCIC, Tatiana GONCHAROV
  • Publication number: 20240368170
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: July 10, 2024
    Publication date: November 7, 2024
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Patent number: 12134649
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 5, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Publication number: 20240362784
    Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.
    Type: Application
    Filed: July 12, 2024
    Publication date: October 31, 2024
    Applicant: GENENTECH, INC.
    Inventor: Fang-Yao HU
  • Patent number: 12129480
    Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 29, 2024
    Assignee: GENENTECH, INC.
    Inventors: Chi Kin Domingos Ng, Yongping Guo Crawford, Amy Shen, Meixia Zhou, Bradley R. Snedecor, Shahram Misaghi, Albert Eric Gao
  • Patent number: 12128103
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: October 29, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Patent number: 12121586
    Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 22, 2024
    Assignee: Genentech, Inc.
    Inventors: Patrick Koenig, Chingwei Vivian Lee, Karthikan Rajagopal, Amin Famili, Germaine Fuh
  • Publication number: 20240344013
    Abstract: Provided herein are methods for quantifying the concentration of multiple metabolites in a sample. Also provided are methods for relative quantification of multiple metabolites in a sample, methods for monitoring the course of a cell culture, and methods for optimising a cell culture.
    Type: Application
    Filed: March 13, 2024
    Publication date: October 17, 2024
    Applicant: Genentech, Inc.
    Inventors: Zijuan LAI, Shahram MISAGHI, Dewakar SANGARAJU, Danming TANG